Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

Cancer Communications

Table 3 Predictive factors for survival by multivariate Cox analysis

Variable	Relapse-free survival		Overall survival
Variable	HR (95% CI)	P value^d	HR (95% CI)	P value^d
Age (> 65 vs. ≤ 65 years)	1.22 (0.68–2.18)	0.508	1.78 (0.86–3.72)	0.123
Primary tumor site (left vs. right)	1.36 (0.81–2.29)	0.244	0.75 (0.39–1.43)	0.382
Tumor grade (G3 vs. G1–2)	0.99 (0.79–1.24)	0.937	0.85 (0.63–1.15)	0.290
pT category (pT3–4 vs. pT1–2)	1.07 (0.55–2.10)	0.843	1.28 (0.47–3.49)	0.624
pN category (pN1–2 vs. pN0)	1.06 (0.70–1.61)	0.775	1.16 (0.66–2.04)	0.617
Preoperative CEA level (> 5 vs. ≤ 5 ng/mL)	0.83 (0.55–1.25)	0.380	1.43 (0.81–2.50)	0.216
Interval from primary tumor resection to liver metastases (> 12 vs. ≤ 12 months)	0.96 (0.55–1.68)	0.881	1.18 (0.58–2.40)	0.649
Number of metastases (> 1 vs. 1 per patient)	0.96 (0.58–1.60)	0.883	0.87 (0.44–1.75)	0.703
Maximum size of metastases (> 5 vs. ≤ 5 cm)	0.82 (0.48–1.41)	0.482	1.48 (0.81–2.71)	0.199
Resection status (R1–2 vs. R0)	2.27 (1.45–3.56)	< 0.001	2.00 (1.13–3.54)	0.017
Radiologic response (SD/PD vs. PR)^a	0.75 (0.49–1.15)	0.184	1.23 (0.67–2.25)	0.497
Duration of preoperative chemotherapy (long vs. short)^b	1.28 (0.86–1.91)	0.231	0.81 (0.46–1.41)	0.451
Chemotherapy backbone (CT with Bev vs. CT only)	1.33 (0.74–2.39)	0.340	1.33 (0.61–2.92)	0.472
Chemotherapy backbone (CT with Cet vs. CT only)	1.24 (0.70–2.22)	0.458	1.68 (0.82–3.42)	0.153
Postoperative chemotherapy (yes vs. no)	0.50 (0.33–0.76)	0.001	0.50 (0.28–0.90)	0.021
TRG (TRG4–5 vs. TRG1–3)^c	1.71 (1.15–2.56)	0.008	1.71 (1.02–2.88)	0.041

Bev bevacizumab, Cet cetuximab, CEA carcinoembryonic antigen, CT chemotherapy, PR partial response, SD stable disease, PD progressive disease, TRG tumor regression grade
^a Because the initial computed tomography or magnetic resonance imaging was performed in other hospitals, 7 of 114 patients who received preoperative chemotherapy without targeted therapies were not evaluable for radiologic response
^b Short duration of preoperative chemotherapy: ≤ 4 cycles for 2-week regimens or ≤ 3 cycles for 3-week regimens; long duration of preoperative chemotherapy: > 4 cycles for 2-week regimens or > 3 cycles for 3-week regimens
^c TRG was evaluated based on the patient-related analysis
^d P < 0.05 was emphasized in italics